Press releaseBusiness Wire
Emmaus Life Sciences
EMMA · OTC
$0.064+$0.014 (+28.00%)TodayMarket closed ·
Prev close $0.05
Latest news
- Press releaseBusiness Wire
Emmaus Life Sciences Reports Quarterly Financial Results
- Press releaseBusiness Wire
Emmaus Life Sciences Reports Quarterly Financial Results
- Press releaseBusiness Wire
Emmaus Life Sciences Reports Annual Financial Results
- Press releaseBusiness Wire
Emmaus Life Sciences Announces Strategic Transaction
- Press releasePRNewswire
Emmaus Life Sciences Reports Quarterly Financial Results
- Press releasePRNewswire
Emmaus Life Sciences Reports Quarterly Financial Results
- Press releasePRNewswire
Emmaus Life Sciences Receives FDA Approval for Endari® Label Enhancements
- Press releasePRNewswire
Emmaus Life Sciences Reports Quarterly Financial Results
- Press releasePRNewswire
Emmaus Life Sciences Reports 2024 Financial Results
- Press releasePRNewswire
Emmaus Life Science Reports Grant of Endari Market Exclusivity In Kingdom of Saudi Arabia
- Press releasePRNewswire
Emmaus Life Sciences Reports Improved Quarterly Financial Results
- NewsAvi Kapoor
ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying
- Press releasePRNewswire
Emmaus Life Sciences Reports Quarterly Financial Results
- Press releasePRNewswire
Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
- Press releasePRNewswire
Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.